Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Ella Day | July 21, 2025 | News story | Medical Communications, Mergers and Acquisitions, Research and Development | Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis (GPP), a rare and potentially life-threatening skin disease.
Under the agreement, LEO Pharma will assume global responsibility for commercialising and advancing the development of Spevigo, building on Boehringer’s launch of the drug in over 40 countries.
Spevigo is the first approved treatment specifically targeting the interleukin-36 receptor, a key immune pathway involved in GPP. The medicine has shown strong efficacy in treating GPP flares and is also being explored for other IL-36-mediated skin conditions.
“We are immensely proud of what Spevigo represents for people living with GPP,” said Shashank Deshpande, chair of Boehringer Ingelheim’s board of managing directors. “LEO Pharma is uniquely positioned to ensure Spevigo reaches its full potential.”
“Partnering to bring Spevigo to more patients is more than a strategic step – it means the opportunity to help people living with GPP by addressing a disease with limited treatment options and aiming to improve their quality of life,” added Christophe Bourdon, chief executive officer of LEO Pharma.
GPP is a chronic inflammatory skin disorder marked by widespread, painful pustules, fatigue, and, in severe cases, organ failure. Its unpredictable course and limited treatment options highlight the critical need for effective therapies like Spevigo.
The transaction is expected to close in late 2025, pending regulatory approvals.
Ella Day
21/7/25
Related Content
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
NICE recommends spevigo for rare and severe psoriasis flares
The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the …
PM Society and CIM launch new leadership programme for pharma marketers
The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to …
